Long‐term hemodynamic effects of ketanserin, a 5‐hydroxytryptamine blocker, in portal hypertensive patients
Julio Vorobioff, Guadalupe Garcia‐Tsao, Roberto Groszmann, Guillermo Aceves, Eduardo Picabea, Roberto Villavicencio, Jorge Hernandez‐Ortiz – 1 January 1989 – Ketanserin, a 5‐hydroxytryptamine‐2 receptor blocker, has been shown to decrease portal pressure in recent acute hemodynamic studies that have been performed both in experimental animals and portal hypertensive patients. The present study was designed to investigate the effects of chronic oral administration of ketanserin in portal hypertensive patients with cirrhosis.